Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Wick, Antje (Heidelberg University Medical Center)
Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke)
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia)
Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute)
Gueorguieva, Ivelina (Eli Lilly and Company)
Burkholder, Tiana (Eli Lilly and Company)
Cleverly, Ann Louise (Eli Lilly and Company)
Estrem, Shawn T. (Eli Lilly and Company)
Wang, Shuaicheng (BioStat Solutions (Estats Units))
Lahn, Michael M.. (Eli Lilly and Company)
Guba, Susan C. (Eli Lilly and Company)
Capper, David (Charité - Universitätsmedizin Berlin)
Rodon Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona
Date: |
2020 |
Abstract: |
The online version of this article contains supplementary material, which is available to authorized users. |
Note: |
Altres ajuts: This trial was funded by Eli Lilly and Company. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Glioblastoma ;
Galunisertib ;
Radiochemotherapy ;
T cells ;
Biomarkers |
Published in: |
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579, ISSN 1573-0646 |
DOI: 10.1007/s10637-020-00910-9
PMID: 32140889
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2020-10-05, last modified 2024-05-22